ACE2 News and Research

RSS

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Researchers examined cases of SARS-CoV-2 infection in fully and partially vaccinated healthcare workers, finding that vaccination provided strong immunity to the virus even though VOCs are on the rise in the non-vaccinated community at large.

7 Jul 2021

Study addresses potential interrelations between AID/APOBECs and the SARS-CoV-2 virus

Together with their multifaceted action mechanisms, activation-induced cytidine deaminase (AID) and so-called APOBEC proteins are important factors in the body's immune response and offer fast and effective protection against a large number of DNA and RNA viruses.

7 Jul 2021

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

6 Jul 2021

SARS-CoV-2 infects and replicates in the salivary glands, study finds

In Brazil, researchers at the University of São Paulo's Medical School (FM-USP) have discovered that SARS-CoV-2 infects and replicates in the salivary glands.

6 Jul 2021

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Serum testosterone status recovery an accurate predictor of survival in male COVID-19 patients

In a study available on the medRxiv* the preprint server, researchers from Spain showed that testosterone trajectories are very accurate individual predictors of survival in male patients with COVID-19. To better understand the relationship between testosterone levels and disease severity, they studied a group of male and female COVID-19 patients assessing their serum and blood biomarkers in association with outcome of disease.

6 Jul 2021

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.

6 Jul 2021

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

A recent tour-de-force study by researchers from the United Kingdom reveals variants of the human angiotensin-converting enzyme 2 (ACE2) that can improve or decrease binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – including two variants with distinct population distributions showing an enhanced affinity for viral spike glycoprotein.

5 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

Study says mRNA COVID vaccines are effective against Lambda variant

Researchers in the United States have conducted a study suggesting that the coronavirus disease 2019 (COVID-19) vaccines that are currently being rolled out in many countries should be effective against the C.37 lineage (lambda variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

A study conducted by researchers from Maryland in the United States has found no correlation between the symptoms that develop following vaccination against coronavirus disease 2019 (COVID-19) and the antibody responses that are generated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

New study attempts to characterize long-COVID in all its complexity

In a new meta-study, a large subset of reports on post-viral complications in individuals following a SARS-CoV-2 infection have been organized and categorized, mapping 287 unique clinical findings related to long-COVID.

5 Jul 2021

Thiol-based mucolytics show potent allosteric inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction

A compelling report, recently released on the bioRxiv* preprint server, describes unexpectedly powerful inhibition of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by thiol-based mucolytic compounds P2119 and P2165, by preventing the virus spike from binding to its host cell receptor, the angiotensin-converting enzyme 2 (ACE2).

5 Jul 2021

Varenicline blocks SARS-CoV-2 infection in cells and animal models

A new paper released on the bioRxiv* preprint server suggests that the nicotinic acetylcholine receptor (nACHR) agonist, varenicline tartrate, has antiviral activity against the virus.

5 Jul 2021

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

The antibodies are capable of neutralizing a wide range of SARS-CoV-2 variants even at sub-nanomolar concentrations. In addition, the combinations of these antibodies reduce the risk of generating escape mutants in vitro. The study is published in the journal Science.

5 Jul 2021

COVID-19 vaccination induces highly variable immunity among the immunocompromised

Researchers in the United States have conducted a study showing that the humoral (antibody) immunity induced by vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – varies significantly among immunocompromised individuals.

4 Jul 2021

The use of flavonoids as antiviral agents against SARS-CoV-2

Researchers in Iran have undertaken a comprehensive review of flavonoids and their antiviral potential against SARS-CoV-2.

2 Jul 2021

Replication of SARS-CoV-2 in nasal ciliated cells could provide a new vaccination target

Researchers have found that nasal ciliated cells are targeted at the onset of COVID-19 infection, which may help to establish nasal mucosal immunity.

2 Jul 2021

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

In a paper recently uploaded to the preprint server bioRxiv* by Schamel et al. (June 25th, 2021) engineered T cells against SARS-CoV-2 are tested against a range of cells in vitro, finding that the treatment could be used to restore cellular immune function and suppress SARS-CoV-2.

1 Jul 2021

Cryo-EM structure of neutralizing antibody 5-7 in complex with SARS CoV-2 spike

Researchers from the US recently reported the 3.7 Å resolution cryo-EM structure of an NTD-directed neutralizing antibody 5-7 that forms a complex with SARS-CoV-2 spike protein. They also presented the neutralization data against VOC and studied the recognized epitope.

1 Jul 2021

ACE2 News and Research

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Study addresses potential interrelations between AID/APOBECs and the SARS-CoV-2 virus

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

SARS-CoV-2 infects and replicates in the salivary glands, study finds

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

Serum testosterone status recovery an accurate predictor of survival in male COVID-19 patients

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

Antibiotic clofoctol shows potential against SARS-CoV-2

Study says mRNA COVID vaccines are effective against Lambda variant

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

New study attempts to characterize long-COVID in all its complexity

Thiol-based mucolytics show potent allosteric inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction

Varenicline blocks SARS-CoV-2 infection in cells and animal models

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

COVID-19 vaccination induces highly variable immunity among the immunocompromised

The use of flavonoids as antiviral agents against SARS-CoV-2

Replication of SARS-CoV-2 in nasal ciliated cells could provide a new vaccination target

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

Cryo-EM structure of neutralizing antibody 5-7 in complex with SARS CoV-2 spike

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News